The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity
Continue reading »
Influenza human challenge study begins at NIH-sponsored clinical trial units
A clinical trial in which healthy adults will be deliberately infected with influenza virus under carefully controlled conditions is recruiting
Continue reading »Beta-blocker trial does not reduce risks for COPD patients
New research from scientists at the University of Alabama at Birmingham published in the New England Journal of Medicine has
Continue reading »Australian trial halves number of tuberculosis cases
Annual community-wide screening for tuberculosis almost halves the number of cases of the deadly disease, a four-year study by Australian
Continue reading »Pomegranate compound with anti-aging effects passes human trial
Urolithin A, a metabolite of biomolecules found in pomegranates and other fruits, could help slow certain aging processes. EPFL spin-off
Continue reading »Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503,
Continue reading »Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia
There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the
Continue reading »Congo starts first-ever trial testing Ebola drugs
Congo has begun the first-ever trial to test the effectiveness and safety of four experimental Ebola drugs, the first time
Continue reading »Anti-CD47 cancer therapy safe, shows promise in small clinical trial
A novel immunotherapy appears safe for use in patients with a type of blood cancer called non-Hodgkin’s lymphoma, according to
Continue reading »Argenx Doses First Patient in Global Phase 3 Registration Trial of Efgartigimod
September 06, 2018 — Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company
Continue reading »